Skip to main content

For US Healthcare Professionals only

CABLIVI (caplacizumab-yhdp) logo
HOME

Real-World Evidence

Patient Enrollment Form

hero

aTTP/iTTP is a rare, life-threatening medical emergency1-6

What is aTTP/iTTP?

Acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP) is a rare, life-threatening, thrombotic microangiopathy manifested as microvascular thrombi and consequent thrombocytopenia, hemolytic anemia, and organ ischemia.2 Thrombotic microangiopathies (TMAs), such as aTTP/iTTP, can be hard to differentiate.6,7

There are 2 types of TTP—aTTP/iTTP and congenital TTP (cTTP), which is caused by mutations in the ADAMTS13 gene. ~95% of TTP cases are aTTP/iTTP.8

Each aTTP/iTTP episode can be unpredictable with microthrombi-driven risks5,9,10

MOD

Risk remains for patients with aTTP/iTTP despite treatment with PEX and immunosuppressive therapy13

25%

Mortality remains high

25% mortality among patients in the study with an aTTP/iTTP diagnosis, including those treated with PEX and immunosuppressive therapy13*

 

*Cohort study of 666 patients with aTTP/iTTP across more than 700 hospitals and 7000 clinics in the US from October 2015 to December 2019.

35%

Thromboembolic events caused by ischemia are common

Nearly 35% of in-hospital TTP deaths (613) were related to ischemia, including MI and stroke, despite receiving PEX.4†

 

†Retrospective claims analysis of hospitalizations with TTP (N=8203).

icon

Exacerbation threatens patients

Up to 55% of patients have ≥1 exacerbation within 30 days of stopping PEX.1‡

 

‡Retrospective review of French Reference Centre for TMA registry (N=388).

icon

Increased risk of stroke through clinical remission§

Stroke after recovery with PEX occurred in 0% (0/22) of patients with mean normal ADAMTS13 activity (>70%) and in 27.6% (8/29) of patients with ADAMTS13 activity ≤70% (P=0.007).14‖

 

‖Cohort study of 170 patients with aTTP/iTTP from 1995 to 2018.

Warning symbol

Early diagnosis of aTTP/iTTP is critical

LEARN HOW
CABLIVI (caplacizumab-yhdp) dots

CABLIVI® (caplacizumab-yhdp) is targeted to prevent microthrombi formation

SEE HOW IT WORKS

§Defined as sustained clinical response either with no PEX and no anti-vWF therapy in the last 30 days or with the attainment of ADAMTS13 remission (partial [between 20% and LLN] or complete [≥LLN]), whichever occurs first.15

ADAMTS13=a disintegrin and metalloproteinase with a thrombospondin type 1 motif, 13; LLN=lower limit of normal; MI=myocardial infarction; PEX=plasma exchange; TTP=thrombotic thrombocytopenic purpura; ULvWF=ultra-large von Willebrand factor; vWF=von Willebrand factor.

INDICATION

CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: 
CABLIVI is contraindicated in patients with previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.

WARNINGS AND PRECAUTIONS:
Hemorrhage:

  • CABLIVI increases the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo.
  • In the postmarketing setting cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI.
  • The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of CABLIVI with drugs affecting hemostasis and coagulation.
  • Avoid concomitant use of CABLIVI with antiplatelet agents, thrombolytic drugs, heparin or anticoagulants. If clinically significant bleeding occurs, interrupt use of CABLIVI. Von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.
  • Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding.

ADVERSE REACTIONS:
In adults, the most common adverse reactions (>15% of patients) are epistaxis, headache, and gingival bleeding. In pediatric patients, the most frequently reported adverse reactions are epistaxis and tachycardia.

DRUG INTERACTIONS:
Concomitant use of CABLIVI with any anticoagulant or antiplatelet agent may increase the risk of bleeding. Avoid concomitant use when possible. Assess and monitor closely for bleeding with concomitant use.

PREGNANCY:
There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.

  • Fetal/neonatal adverse reactions: CABLIVI may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
  • Maternal adverse reactions: All patients receiving CABLIVI, including pregnant women, are at risk for bleeding. Pregnant women receiving CABLIVI should be carefully monitored for evidence of excessive bleeding.

Please see full Prescribing Information.
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs.

INDICATION

IMPORTANT SAFETY INFORMATION

References: 1. Grall M, Azoulay E, Galicier L, et al. Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: causes of diagnostic errors and consequence on outcome. Experience of the French Thrombotic Microangiopathies Reference Centre. Am J Hematol. 2017;92(4):381-387. doi:10.1002/ajh.24665 2. Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500-1511. doi:10.1182/blood-2009-09-243790 3. Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost. 2017;15(7):1448-1452. doi:10.1111/jth.13716 4. Goel R, King KE, Takemoto CM, Ness PM, Tobian AAR. Prognostic risk-stratified score for predicting mortality in hospitalized patients with thrombotic thrombocytopenic purpura: nationally representative data from 2007 to 2012. Transfusion. 2016;56(6):1451-1458. doi:10.1111/trf.13586 5. Masias C, Wu H, McGookey M, Jay L, Cataland S, Yang S. No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry. Am J Hematol. 2018;93(3):E73-E75. doi:10.1002/ajh.25002 6. Coppo P, Veyradier A. Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med. 2012;41(3 pt 2):e163-e176. doi:10.1016/j.lpm.2011.10.024 7. Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The differential diagnosis and treatment of thrombotic microangiopathies. Dtsch Arztebl Int. 2018;115(19):327-334. doi:10.3238/arztebl.2018.0327 8. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2486-2495. doi:10.1111/jth.15006 9. Schieppati F, Russo L, Marchetti M, et al. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: a multi-institutional study. Am J Hematol. 2020;95(8):953-959. doi:10.1002/ajh.25845 10. Knoebl P, Cataland S, Peyvandi F, et al. Efficacy andsafety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. J Thromb Haemost. 2019;18(2):479-484. doi:10.1111/jth.14679 11. Joly BS, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura. Blood. 2017;129(21):2836-2846. doi:10.1182/blood-2016-10-709857 12. Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3:17020. doi:10.1038/nrdp.2017.20 13. Adeyemi A, Razakariasa F, Chiorean A, De Passos Sousa R. Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States. Res Pract Thromb Haemost. 2022;6(6):e12802. doi:10.1002/rth2.12802 14. Upreti H, Kasmani J, Dane K, et al. Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors. Blood. 2019;134(13):1037-1045. doi:10.1182/blood.2019001056 15. Cuker A, Cataland SR, Coppo P, et al; International Working Group for Thrombotic Thrombocytopenic Purpura. Redefining outcomes in immune TTP: an international working group consensus report. Blood. 2021;137(14):1855-1861. doi:10.1182/blood.2020009150

CABLIVI and Sanofi are registered trademarks of Sanofi or an affiliate. MAT-US-2024153-v7.0-01/2026 Last Updated: January 2026.

Back to top
Back to top
SitemapLegal NoticePrivacy PolicyCookie PolicyDo Not Sell or Share My Personal InformationContactAccessibility Statement
© 2026 Sanofi. All rights reserved.